• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioCorRx to meet with the FDA for injectable, sustained-release opioid addiction therapy

May 25, 2017 By Sarah Faulkner

BioCorRxBioCorRx (OTC:BICX) said today that the FDA has granted the anti-addiction developer a pre-investigational new drug meeting, scheduled for Sept. 19.

The Anaheim, Calif.-based company said it is slated to review the development and marketing plan for BICX101, an injectable, sustained-release formulation of naltrexone as a therapy for opioid addiction and alcohol use disorders.

At the pre-IND meeting, BioCorRx said it plans to win a nod from the FDA regarding its proposal to submit a new drug application under Section 505(b)(2). This type of approval pathway would allow BioCorRx to use previous safety and efficacy data collected by other groups to support its product.

“We are appreciative of the FDA’s response and look forward to meeting with them to present our plan for BICX101,” president & CEO Brady Granier said in prepared remarks. “Between now and the meeting date, we will continue to conduct more preclinical studies on BICX101 at Covance in order to collect additional data which will go into our briefing document to the FDA and IND filing. We continue to be excited about the potential for BICX101 to be utilized for multiple substance use disorder indications in the future.”

Also this week, FDA commissioner Dr. Scott Gottlieb urged his staff to consider “more forceful” efforts to curb the opioid epidemic that claims 91 lives in America every day, according to the Centers for Disease Control & Prevention.

“As commissioner, my highest initial priority is to take immediate steps to reduce the scope of the epidemic of opioid addiction,” Gottlieb wrote in a blog post. “I believe it is within the scope of FDA’s regulatory tools – and our societal obligations – to take whatever steps we can, under our existing legal authorities, to ensure that exposure to opioids is occurring under only appropriate clinical circumstances, and for appropriate patients.”

Gottlieb established an Opioid Policy Steering Committee and posed to them 3 questions: Are there circumstances under which the FDA should mandate education for healthcare professionals regarding appropriate prescribing habits? Are there steps the FDA can take to ensure that opioid prescriptions reflect the clinical circumstances? Is the FDA adequately considering the risk of abuse and misuse as a part of the drug review and approval process?

“In the coming days, I’ll continue to work closely with the senior leadership of FDA,” Gottlieb wrote. “I want to know what other important ideas my colleagues at FDA may have, so that we can lean even further into this problem, using our full authorities to work toward reducing the scope of this epidemic.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: BioCorRx

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS